Impact of adherence to interferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study

Clinical Drug Investigation

Volumn 30, Issue 2, 2010, Pages 89-100

  Steinberg, Stephanie C ^a   Faris, Richard J ^b   Chang, Cyril F ^a   Chan, Andrew ^c   Tankersley, Mark A ^b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b Accredo Health Group Inc   (United States)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; EXTAVIA; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME VARIABLE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; CANADA; COHORT STUDIES; EMERGENCY MEDICAL SERVICES; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OFFICE VISITS; PATIENT COMPLIANCE; RECURRENCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 75149189869     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533330-000000000-00000     Document Type: Article

References (53)

1. Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd, 2000
2. National multiple sclerosis society [online]. Available from URL: http://www.nationalmssociety.org/about-multiplesclerosis [Accessed 2009 Oct 12]
3. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan; 58 (2): 169-178
4. Manfredonia F, Pasquali L, Dardano A, et al. Review of the clinical evidence for interferon B 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2008 Apr 4 (2): 321-336
5. Lublin F, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532
6. Johnson KL, Kuehn CM, Yorkston KM, et al. Patient perspectives on disease-modifying therapy in multiple sclerosis. Int J MS Care 2006; 8: 11-18
7. TreadwayK, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy inMS. J Neurol 2009 April; 256 (4): 568-576
8. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patient and society? Drugs 2003; 63: 525-533
9. Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009 Jun; 31 (6): 1142-1157
10. Jewell S. Issues in adherence: initiating and maintaining patients on immunotherapy. Multiple Sclerosis Pro 2001 [online]. Available from URL: http://www.multiplesclero sispro.com/admin/templates/Template-Nurse-Issues.as px?artic. [Accessed 2009 Oct 18]
11. National Institute of Neurological Disorders and Stroke: 2009 [online]. Available from URL: http://www.ninds.nih. gov/disorders/multiplesclerosis/ detail-multiple-sclerosis.htm [Accessed 2009 Nov 10]
12. Kolbelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: an observational study in Germany. HEPAC 2001; 2: 60-68
13. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002; 58: 37-43
14. Grima DT, Torrance GW, Francis G, et al. Cost and healthrelated quality of life consequences of multiple sclerosis. Mult Scler 2000; 6 (2): 91-98
15. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002; 104 (3): 272-275
16. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003 Sept; 3: 17
17. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon b therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008; 59 (3-4): 131-135
18. Recognizing nonadherence in patients with MS: defining adherence [online].Available fromURL: http://www.medscape. com/view article/579661 3 [Accessed 2009 Aug 2]
19. Vercellino M, Romagnolo A, Mattioda S, et al. Multiple sclerosis relapses: amultivariable analysis of residual disability determinants. Acta Neurol Scand 2009 Feb; 119 (2): 126-130
20. Klauer T, Zette UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008 Dec; 255 Suppl. 6: 87-92
21. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008 Apr; 17 (6): 565-576
22. Zycynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000; 2 (6): 510-514
23. Cramer JA, Benedict A, Muszbeck N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dysplipidaemia: a review. Int J Clin Practice 2008 Jan; 62 (1): 76-87
24. Revel M. Interferon-B in the treatment of relapsingremitting multiple sclerosis. Pharmacol Therap 2003 Oct; 100 (1): 49-62
25. Portaccio E, Amato MP. Improving compliance with interferon- beta therapy in patients with multiple sclerosis. CNS Drugs 2009; 23 (6): 453-462
26. MacLean HJ, Freedman MS. Immunologic therapy for relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 2001 May; 1 (3): 277-285
27. McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 2004; 18 (8): 521-546
28. Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006 May; 44 (5): 471-477
29. Fairman K, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm 2000; 6: 499-506
30. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of theGlaucoma Adherence and Persistence Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48: 5052-5057
31. Johnson RE, Volmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991; 39: 1079-1084
32. Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmacoepidemiol 1996; 5 (1): 3-15
33. Lau HS, De Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50 (5): 619-625
34. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 Aug; 48 (8): 999-1009
35. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 Jul; 7 (11): 449-457
36. Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005 Aug; 132: 487-497
37. Steiner JF, Earnest MA. The language of medication taking. Ann Intern Med 2000; 132: 926-930
38. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence using retrospective databases. Value Health 2007 Jan-Feb; 10 (1): 3-12
39. Ruggieri RM, Settipiani N, Viviano L, et al. Long-term interferon-b treatment for multiple sclerosis. Neurol Sci 2003 Dec; 24 (5): 361-364
40. Schumacker GA, Beebe G, Kebler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-568
41. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. MedHypotheses 1986 Oct; 21: 193-200
42. Buljevac D, Hop WC, Reedeker AC, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 2003; 327: 646-649
43. Putnam KG, Buist DS, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology 2002 May; 13 (3): 340-346
44. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing mul|iple sclerosis. Ann Neurol 2004 Oct; 39 (3): 285-294
45. Tang J, Faris RJ. Exploring the impact of dispensing channel on medication adherence among multiple sclerosis patients. ISPOR 14th Annual International Meeting; 2009 May 16-20; Orlando (FL)
46. Garcia DO, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30 (1): 105-110
47. Brigido LF, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS 2001 Nov; 15 (11): 587-593
48. DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther 2001; 18 (4): 163-173
49. Gwadry-Sridhar F, Manias E, Zhang Y, et al. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 2009 Feb; 31 (2): 421-435
50. Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005 May-Jun; 45 (3): 371-375
51. Munschauer FE, Tyree J. Persistency in patient with multiple sclerosis. Paper presented at the Annual Meeting of the Consortium of MS Centers (CMSC) 2004 Jun 4; Toronto (ON)
52. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554
53. Kreuger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005 Jul-Aug; 22 (4): 313-356